Birmingham, UK
Francesca Montanari Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA
Katharine B. Moosic Department of Medicine and Department of Pathology, Division of Hematology and Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA
Franck Morschhauser Department of Hematology, Lille University Hospital, Lille, France
Wataru Munakata Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
Owen A. O’Connor Department of Medicine, Division of Hematology and Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA, and Program for T‐Cell Lymphoma Research, Department of Microbiology, Immunology and Cancer Research University of Virginia Cancer Center, Charlottesville, VA, USA
Kristine C. Olson Department of Medicine, Division of Hematology and Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA
Juan Alejandro Ospina‐Idárraga Los Cobos Medical Center, Instituto Nacional de Cancerología, Universidad El Bosque, Bogotá, Colombia
Neval Ozkaya Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, MD, USA
Pier Paolo Piccaluga Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy
Stefano A. Pileri Hematopathology Division, European Institute of Oncology, IRCCS, Milan, Italy
H. Miles Prince Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
Barbara Pro Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
Dejan Radjeski Sir Charles Gardner Hospital, Perth, Western Australia, Australia
Bethanie Rooke Department of Dermatology, University Hospital, Birmingham, UK
Tatsuhiro Sakamoto Department of Hematology, Faculty of Medicine, University of Tsukuba Hospital, Tsukuba, Japan, and Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Mamiko Sakata‐Yanagimoto Department of Hematology, Faculty of Medicine, University of Tsukuba Hospital, Tsukuba, Japan, and Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Ahmed Sawas Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA
Julia Scarisbrick Department of Dermatology, University Hospital, Birmingham, UK
Luigi Scotto Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA
Jennifer Shingleton Duke Cancer Institute, Center for Genomic and Computational Biology, Duke University, Durham, NC, USA
Raksha Shrestha Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Andrei Shustov Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; and Seattle Cancer Care Alliance, Seattle, WA, USA
Tetiana Skrypets Department of Surgical, Medical and Dental Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Reggio Emilia, Italy
Craig R. Soderquist Division of Hematopathology, Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA
Robert N. Stuver Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
Ritsuro Suzuki Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan
Kensei Tobinai Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
Claudio Tripodo Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy, and Histopathology Unit, FIRC Institute of Molecular Oncology, Milan, Italy
Lorenz Truempe Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany
Sean Whittaker Guy’s and St Thomas’ National Health Service Foundation Trust, London, UK
Mina Xu Department Pathology, Yale University School of Medicine, New Haven, CT, USA
Amulya Yellala Division of Oncology‐Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
Anas Younes Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Jasmine Zain Department of Hematology/Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA
Pier Luigi Zinzani IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna, Italia
About the Companion Website
Don’t forget to visit the companion web site for this book:
www.wiley.com/go/OConnor/Peripheral_T‐cell_Lymphomas
There you will find valuable materials, including:
Figures and Tables from within the book
Scan this QR code to visit the companion website:
1 The Fundamentals of T‐cell Lymphocyte Biology
Claudio Tripodo1,2 and Stefano A. Pileri3
1 Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy
2 Histopathology Unit, FIRC Institute of Molecular Oncology, Milan, Italy
3 Hematopathology Division, European Institute of Oncology, IRCCS, Milan, Italy
TAKE HOME MESSAGES
The natural diversity of T cells in normal immune system functions contributes – in part – to the diversity of T‐cell malignancies.
CD4‐positive T lymphocytes, also called T helper (Th) cells, are divided into a diverse repertoire of T lymphocytes (e.g. Th1, Th2, and Th17), in part defined by the cytokine profile they elaborate.
Th1 and Th2 lymphocytes can also be classified based on the expression of the transcription factors T‐bet and GATA3. These factors can be prognostic in peripheral T‐cell non‐Hodgkin lymphomas derived from these cells (with GATA3 being associated with a poor prognosis).
Introduction